Cargando…

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial(1)

BACKGROUND: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson’s disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the Eu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbruzzese, Giovanni, Kulisevsky, Jaime, Bergmans, Bruno, Gomez-Esteban, Juan C., Kägi, Georg, Raw, Jason, Stefani, Alessandro, Warnecke, Tobias, Jost, Wolfgang H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990425/ https://www.ncbi.nlm.nih.gov/pubmed/33104040 http://dx.doi.org/10.3233/JPD-202224

Ejemplares similares

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Efficacy of Safinamide and Gender Differences During Routine Clinical Practice
por: Pellecchia, Maria T., et al.
Publicado: (2021)

Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
por: Bergmans, Bruno, et al.
Publicado: (2022)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients
por: Cattaneo, Carlo, et al.
Publicado: (2020)

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
por: Gómez-López, Ana, et al.
Publicado: (2021)

The effects of safinamide on dysphagia in Parkinson’s disease
por: Hirano, Makito, et al.
Publicado: (2023)

Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
por: De Masi, Claudia, et al.
Publicado: (2022)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

The effects of safinamide according to gender in Chinese parkinsonian patients
por: Pellecchia, M. T., et al.
Publicado: (2023)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
por: Martí-Andrés, Gloria, et al.
Publicado: (2019)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
por: Peña, Esteban, et al.
Publicado: (2021)

Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
por: Cilia, Roberto, et al.
Publicado: (2023)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Chimeric Agents Derived from the Functionalized Amino Acid, Lacosamide, and the α-Aminoamide, Safinamide: Evaluation of Their Inhibitory Actions on Voltage-Gated Sodium Channels, and Antiseizure and Antinociception Activities and Comparison with Lacosamide and Safinamide
por: Park, Ki Duk, et al.
Publicado: (2014)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021)

Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021)

Establishment of a sensitive UPLC-MS/MS method to quantify safinamide in rat plasma
por: Wang, Ying, et al.
Publicado: (2023)

Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study
por: De Micco, Rosa, et al.
Publicado: (2021)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
por: Bette, Sagari, et al.
Publicado: (2018)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021)

Overall Efficacy and Safety of Safinamide in Parkinson’s Disease: A Systematic Review and a Meta-analysis
por: Giossi, Riccardo, et al.
Publicado: (2021)

Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review
por: Sanchez Alonso, Pilar, et al.
Publicado: (2023)

A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease
por: Abdelalem Aziz Ahmed, Mohamed
Publicado: (2019)

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
por: Labandeira, Carmen M., et al.
Publicado: (2021)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rvplih36q8ho7rci6spp4379u5